Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: A possible molecular pathway of mucosal healing in ulcerative colitis

Journal of Clinical Pathology

Volumn 64, Issue 11, 2011, Pages 968-972

  Ierardi, Enzo ^a   Giorgio, Floriana ^a   Zotti, Mariangela ^a   Rosania, Rosa ^a   Principi, Mariabeatrice ^b   Marangi, Stefania ^c   Valle, Nicola Della ^a   De Francesco, Vincenzo ^a   Di Leo, Alfredo ^b   Ingrosso, Marcello ^c   Panella, Carmine ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; FIBROBLAST GROWTH FACTOR 2; INFLIXIMAB; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENTERITIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRRITABLE COLON; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RECTUM BIOPSY; RETROSPECTIVE STUDY; STROMA CELL; ULCER HEALING; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; DOWN-REGULATION; FEMALE; FIBROBLAST GROWTH FACTOR 2; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RECTUM; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNDECAN-1; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 80054963453     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.086892     Document Type: Article

References (17)

1. Pucilowska JB, Williams KL, Lund P. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000;279:G653-9.
2. Saunders S, Jalkanen M, O'Farrell S, et al. Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol 1989;108:1547-56. (Pubitemid 19097059)
3. Day R, Ilyas M, Daszak P, Talbot I, et al. Expression of Syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 1999;44:2508-15. (Pubitemid 30027369)
4. Fernig DG, Gallagher JT. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res 1994;5:353-77. (Pubitemid 124004659)
5. Day R, Forbes A. Heparin, cell adhesion and pathogenesis of inflammatory bowel disease. Lancet 1999;354:62-4.
6. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999;5:44-60.
7. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alphadependent angiogenesis. Mol Cell Biol 1997;17:4015-23. (Pubitemid 27281877)
8. Ierardi E, Giorgio F, Rosania R, et al. Mucosal assessment of tumor necrosis factor alpha levels on paraffined samples: a comparison between immunohistochemistry and real time polymerase chain reaction. Scand J Gastroenterol 2010;45:1007-8.
9. Principi M, Day R, Marangi S, et al. Differential immunohistochemical expression of Syndecan-1 and tumor necrosis factor alpha in colonic mucosa of patients with Crohn's disease. Immunopharmacol Immunotoxicol 2006;28:185-95. (Pubitemid 44180237)
10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987;317:1625-9. (Pubitemid 18010466)
11. Ierardi E, Meucci G, Hassan C, et al. Tumour necrosis factor alpha in segmental colitis associated with diverticula. Dig Dis Sci 2008;53:1865-8.
12. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169-93.
13. Day RM, Hao X, Ilyas M, et al. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 1999;434:121-5. (Pubitemid 29184989)
14. Hassan C, Ierardi E, Burattini O, et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007;39:811-17. (Pubitemid 47215583)
15. Hassan C, Zullo A, De Francesco V, et al. Tumor necrosis factor alpha in ulcerative colitis and diverticular disease associated colitis. Endocr Metab Immune Disord Drug Targets 2007;7:187-94. (Pubitemid 47496625)
16. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 2009;102:823-8.
17. Morson BC, Dawson IMP. Gastro-intestinal Pathology. 2nd edn. Oxford: Blackwell Scientific Publications, 1979:530-3.